Company Overview

For personal use only (b) Frost & Sullivan Market Report as commissioned by APIRX, Sept. 2021, market opportunity is medications and other, where other includes visits to physicians, in/out patient costs (c) Frost & Sullivan Market Report as commissioned by APIRX, Sept. 2021, market opportunity is Adolescent Substance Abuse (g) ResearchandMarkets, "Outlook on the Glaucoma Therapeutics Global Market", 2020-2026", Oct. 22. 2021 (o) Worldwide Market Reports, "Smoking Cessation and Nicotine De-Addiction Products Market", May 2018 (p) Future Market Insights, "Dry Eye Syndrome Treatment Market", July 2017 (q) Precedence Research "Cannabis Extract Market", Mar. 2020; includes THC, CBD, CBG and other Incannex Clinical Project CanChew Plus Gastro: IBS CanChew RX Gastro: IBD SuppoCan (Suppository) Gastro: IBD Oraximax Gingivitis and Periodontitis CheWell Addiction: Cannabis Dependence CanQuit Addiction: Tobacco Smoking Cessation CanQuit O Addiction: Opioid Addiction APIRX-1601 Skin: Vitiligo APIRX-1602 Skin: Psoriasis APIRX-1603 Skin: Atopic Dermatitis APIRX-1701 Opth: Glaucoma APIRX-1702 Opth: Dry Eye Syndrome APIRX-1801 Ultrapure THC APIRX-1802 Ultrapure CBD APIRX-1803 Ultrapure CBG Addressable Market Opportunity (in US$) $40B (U.S.) in '21 (d) $2.78B (U.S.) by '28 (r) $2.78B (U.S.) by 28 (r) $42B (U.S. and Europe) in '21 (a) $64B (U.S.) in '21 (c) $47.75B (Global) by '24, 17.3 % CAGR (0) $64B (U.S.) in '21 (c) $0.1B (Global) in '21 (b) $0.5B (Global) in '21 (b) $1.1B (Global) in '21 (b) $10.4B (Global) by '26, 6.3% CAGR (g) $6.6B (Global) by '27, 6.4% CAGR (p) $31.5B (Global) by '30; 18.6% CAGR (q) $31.5B '30; 18.6% CAGR (q) $31.5B (Global) by '30; 18.6% CAGR (q) Stage of Development Phase 2A Completed Pre-clinical Pre-clinical Clinical Stage Pre-clinical Pre-clinical Pre-clinical Phase 2 completed Phase 2A completed Phase 2A completed Pre-clinical Pre-clinical Developed eloped Developed Regulatory Stage of Development Pre-IND, ethical approval Pre-regulatory Pre-regulatory 510(k) pre-market submission to FDA Pre-IND ready for submission Pre-regulatory Pre-regulatory Pre-IND drafting Pre-IND drafting Pre-IND drafting Pre-regulatory Pre-regulatory Next Steps Phase 2B Phase 1 Phase 1 Phase 2 Phase 1 Phase 1 Phase 1 Phase 1 Phase 1 Phase 1 in vitro studies in vitro studies Investor Presentation Relevant Patents Granted Granted Granted Granted Drafting Granted Granted 2x Granted, 1x Pending 2x Granted, 1x Pending 2x Granted, 1x Pending Granted Granted Granted Granted Granted 8

View entire presentation